BACKGROUND
Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced melanoma, but optimal treatment duration remains unclear. Most patients are treated until two years, treatment limiting toxicity (TLT), or progression. This study evaluates real-world outcomes after elective discontinuation of ICIs fol...
R. Jurlander, T. H. Borch, S. Petersen et al.· European Journal of Cancer· 0 citations
It is demonstrated that pharmacological inhibition of the glyoxalase system—the major pathway for MGO detoxification—restores drug sensitivity in patient-derived cells and xenograft models, revealing a context-dependent metabolic vulnerability in AKR1A1 loss conditions.
Effective T cell–based immunotherapies require functional receptors that can be engineered and redeployed to recognize tumor-restricted antigens. Noncanonical peptides arising from transcription outside annotated protein-coding regions expand the antigenic landscape of cancer; however, systematic strategies to biologic...
T. Hulen, M. D. Crowther, Luke Schuster et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.